BortSimpson
Member
- Joined
- Feb 3, 2020
- Messages
- 449
I'm thinking we should have a discussion thread with anti-vaccine arguments that we can refer to when we need to convince others. Below are 2 safety studies - one from Pfizer and the other from Moderna - that aren't even scheduled to complete until October 2022 (for Moderna) and May 2023 (for Pfizer). So TPTB are pushing vaccines on everyone before these safety studies are even close to being complete?!
Pfizer clinical trial ("Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals") has an "Estimated Study Completion Date" of May 2, 2023
https://clinicaltrials.gov/ct2/show/NCT04368728
[TABLE="class: ct-layout_table tr-tableStyle tr-studyInfo, width: 1885"]
[TR]
[TD="align: right"]Study Type :[/TD]
[TD]Interventional (Clinical Trial)[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Enrollment :[/TD]
[TD]43998 participants[/TD]
[/TR]
[TR]
[TD="align: right"]Allocation:[/TD]
[TD]Randomized[/TD]
[/TR]
[TR]
[TD="align: right"]Intervention Model:[/TD]
[TD]Parallel Assignment[/TD]
[/TR]
[TR]
[TD="align: right"]Masking:[/TD]
[TD]Triple (Participant, Care Provider, Investigator)[/TD]
[/TR]
[TR]
[TD="align: right"]Primary Purpose:[/TD]
[TD]Prevention[/TD]
[/TR]
[TR]
[TD="align: right"]Official Title:[/TD]
[TD]A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS[/TD]
[/TR]
[TR]
[TD="align: right"]Actual Study Start Date :[/TD]
[TD]April 29, 2020[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Primary Completion Date :[/TD]
[TD]May 2, 2023[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Study Completion Date :[/TD]
[TD]May 2, 2023[/TD]
[/TR]
[/TABLE]
Moderna clinical trial ("A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19") has an "Estimated Study Completion Date" of October 27, 2022
https://clinicaltrials.gov/ct2/show/NCT04470427
[TABLE="class: ct-layout_table tr-tableStyle tr-studyInfo, width: 1885"]
[TR]
[/TR]
[TR]
[TD="align: right"]Study Type :[/TD]
[TD]Interventional (Clinical Trial)[/TD]
[/TR]
[TR]
[TD="align: right"]Actual Enrollment :[/TD]
[TD]30420 participants[/TD]
[/TR]
[TR]
[TD="align: right"]Allocation:[/TD]
[TD]Randomized[/TD]
[/TR]
[TR]
[TD="align: right"]Intervention Model:[/TD]
[TD]Parallel Assignment[/TD]
[/TR]
[TR]
[TD="align: right"]Masking:[/TD]
[TD]Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)[/TD]
[/TR]
[TR]
[TD="align: right"]Masking Description:[/TD]
[TD]Part A is observer-blind. During Part B participants may request to be unblinded by scheduling a Participant Decision clinic visit.[/TD]
[/TR]
[TR]
[TD="align: right"]Primary Purpose:[/TD]
[TD]Prevention[/TD]
[/TR]
[TR]
[TD="align: right"]Official Title:[/TD]
[TD]A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older[/TD]
[/TR]
[TR]
[TD="align: right"]Actual Study Start Date :[/TD]
[TD]July 27, 2020[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Primary Completion Date :[/TD]
[TD]October 27, 2022[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Study Completion Date :[/TD]
[TD]October 27, 2022[/TD]
[/TR]
[/TABLE]
Pfizer clinical trial ("Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals") has an "Estimated Study Completion Date" of May 2, 2023
https://clinicaltrials.gov/ct2/show/NCT04368728
[TABLE="class: ct-layout_table tr-tableStyle tr-studyInfo, width: 1885"]
[TR]
[TD="align: right"]Study Type :[/TD]
[TD]Interventional (Clinical Trial)[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Enrollment :[/TD]
[TD]43998 participants[/TD]
[/TR]
[TR]
[TD="align: right"]Allocation:[/TD]
[TD]Randomized[/TD]
[/TR]
[TR]
[TD="align: right"]Intervention Model:[/TD]
[TD]Parallel Assignment[/TD]
[/TR]
[TR]
[TD="align: right"]Masking:[/TD]
[TD]Triple (Participant, Care Provider, Investigator)[/TD]
[/TR]
[TR]
[TD="align: right"]Primary Purpose:[/TD]
[TD]Prevention[/TD]
[/TR]
[TR]
[TD="align: right"]Official Title:[/TD]
[TD]A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS[/TD]
[/TR]
[TR]
[TD="align: right"]Actual Study Start Date :[/TD]
[TD]April 29, 2020[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Primary Completion Date :[/TD]
[TD]May 2, 2023[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Study Completion Date :[/TD]
[TD]May 2, 2023[/TD]
[/TR]
[/TABLE]
Moderna clinical trial ("A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19") has an "Estimated Study Completion Date" of October 27, 2022
https://clinicaltrials.gov/ct2/show/NCT04470427
[TABLE="class: ct-layout_table tr-tableStyle tr-studyInfo, width: 1885"]
[TR]
[/TR]
[TR]
[TD="align: right"]Study Type :[/TD]
[TD]Interventional (Clinical Trial)[/TD]
[/TR]
[TR]
[TD="align: right"]Actual Enrollment :[/TD]
[TD]30420 participants[/TD]
[/TR]
[TR]
[TD="align: right"]Allocation:[/TD]
[TD]Randomized[/TD]
[/TR]
[TR]
[TD="align: right"]Intervention Model:[/TD]
[TD]Parallel Assignment[/TD]
[/TR]
[TR]
[TD="align: right"]Masking:[/TD]
[TD]Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)[/TD]
[/TR]
[TR]
[TD="align: right"]Masking Description:[/TD]
[TD]Part A is observer-blind. During Part B participants may request to be unblinded by scheduling a Participant Decision clinic visit.[/TD]
[/TR]
[TR]
[TD="align: right"]Primary Purpose:[/TD]
[TD]Prevention[/TD]
[/TR]
[TR]
[TD="align: right"]Official Title:[/TD]
[TD]A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older[/TD]
[/TR]
[TR]
[TD="align: right"]Actual Study Start Date :[/TD]
[TD]July 27, 2020[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Primary Completion Date :[/TD]
[TD]October 27, 2022[/TD]
[/TR]
[TR]
[TD="align: right"]Estimated Study Completion Date :[/TD]
[TD]October 27, 2022[/TD]
[/TR]
[/TABLE]